Market Overview

Gilead Enters Licensing Agreement With Trianni for Use of Trianni Transgenic Human Monoclonal Antibody Discovery Platform

Share:

Gilead Sciences, Inc. (NASDAQ:GILD) and Trianni, Inc. ("TRIANNI") today
announced that the companies have entered into a license agreement that
grants Gilead the use of the Trianni transgenic human monoclonal
antibody discovery platform to support the company's drug discovery
efforts.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180904005088/en/

"We look forward to integrating Trianni's technology into our research
and development program," said Bill Lee, PhD, Executive Vice President
of Research, Gilead. "This platform will help enhance our ability to
discover human antibodies and to develop new therapies in areas of unmet
medical need."

"Trianni is very happy that Gilead has chosen the Trianni discovery
platform," said Matthias Wabl, PhD, Chairman, President and CEO of
Trianni. "We are confident that the cutting-edge genomic design of the
Trianni discovery platform, which combines the complete human antibody
repertoire with wild-type mouse immune responses to any target antigen,
will nicely complement Gilead's drug discovery programs."

No financial details were disclosed.

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that
discovers, develops and commercializes innovative medicines in areas of
unmet medical need. The company strives to transform and simplify care
for people with life-threatening illnesses around the world. Gilead has
operations in more than 35 countries worldwide, with headquarters
in Foster City, California. For more information on Gilead Sciences,
please visit the company's website at www.gilead.com.

About Trianni, Inc.

Trianni, Inc. is a privately held biotech company specializing in
antibody discovery technology. Trianni's lead technology is a
next-generation transgenic discovery platform enabling efficient
generation of fully-human monoclonal antibodies. The design of the
Trianni discovery platform leverages advances in DNA synthesis and
genomic modification technology. Trianni is headquartered in South San
Francisco, CA. Additional information about Trianni is available through
its corporate website, www.trianni.com.

Gilead Forward-Looking Statements

This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 that are
subject to risks, uncertainties and other factors, including the risk
that the parties may not realize the potential benefits of this
licensing arrangement. All statements other than statements of
historical fact are statements that could be deemed forward-looking
statements. These risks, uncertainties and other factors could cause
actual results to differ materially from those referred to in the
forward-looking statements. The reader is cautioned not to rely on these
forward-looking statements. These and other risks are described in
detail in Gilead's Quarterly Report on Form 10-Q for the quarter ended
June 30, 2018, as filed with the U.S. Securities and Exchange
Commission. All forward-looking statements are based on information
currently available to Gilead, and Gilead assumes no obligation to
update any such forward-looking statements.

View Comments and Join the Discussion!